Search

Strong cash position at year-end 2025: $33.3 million (€28.4 million).

The integration of polygenic risk models based on genome-wide association studies (GWAS) enables healthcare professionals to incorporate genetic risk stratification into clinical practice and advance

The second edition of this high-level event will take place on March 24 in Brussels under the motto “Driving Impact: Bio-based innovation for a competitive, sustainable Europe”

The Dutch company continues to promote the deep tech ecosystem in Spain.

Condalab invites you to the second edition of our Digital Cell Biology Conference, a free online event aimed at professionals working in biomedical or veterinary research, where cellular models and

The company is the leading private entity in financing in Extremadura and in Cluster 6 - Food, bioeconomy, natural resources, agriculture, and environment of the European Union's research and

Despite advances in early detection, risk-adapted treatment, and precision oncology, the findings indicate that prostate cancer continues to generate high and increasing costs, particularly in

Meet Molefy Pharma, our new member. We spoke with Alfonso de Egaña, CEO.

The collaboration combines IQM-CSIC’s expertise in compound design, synthesis, and biological evaluation with ProtoQSAR’s capabilities in predictive modeling.

GSK joins the cluster as a Business Partner with a focus on connecting stakeholders, generating knowledge and transforming the healthcare system.

The roundtable will address the use of artificial intelligence to integrate biomedical and contextual data (wearables, GPS, training load, etc.), through a Digital Twin.

The Axencia Galega de Innovación (Gain) has begun drafting the new Biotechnology Excellence Strategy 2026-2030 in Galicia with a survey aimed at professionals in the sector. The objective is to

The UTE BBZS_CAR-T consortium is advancing the CART_Andalucía project with a modular and scalable platform aimed at enabling more sustainable and effective access to advanced therapies.

These studies have provided new, robust data to assist decision-makers in resource allocation and have offered deep insights into the disease burden on the Spanish National Health System and the

For the biotechnology sector, it represents both a challenge and an opportunity, as it requires improved information management and the adoption of circular practices that promote more sustainable